E2, 0.17 mg/kg body weight/day); and OVX with BHH10 in graded doses (250, 500, or 750 mg/kg/day). Daily oral administration of BHH10, ALN or E2 started on week 2 after OVX and continued for 12 weeks. Body and uterus weight, serum biochemical bone turnover markers, bone mineral density (BMD), and microarchitectural parameters were assessed. Results: BHH10 inhibited OVX-induced body weight gain, uterus atrophy, and significantly decreased levels of the bone formation markers serum alkaline phosphatase (ALP) and osteocalcin (OCN), and the bone resorption parameter C-telopeptide type 1 collagen (CTX). BHH10 also notably enhanced BMD and bone microstructure in both total femur and femoral neck measurements compared to OVX rats. Conclusions: These results suggested that BHH10 administration improved biochemical markers of bone metabolism, bone biomechanical quality, and bone structural integrity in OVX rats. The potent anti-osteoporosis effect of BHH10 might be mediated by its action of stimulating bone formation and regulating bone resorption with no significant toxicity.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.